Interview with Kalman Petro, Managing Director, Actavis BV
A very strong phrase that we recently came across describes a “war going on in the generics industry” as a result of the preference policy, which people have claimed has…
Address: Vijzelmolenlaan 9, 3447 GX, Woerden,Netherlands
Tel: +31 348574222
Web: http://www.b-ms.nl/
The headquarters of Bristol-Myers Squibb (B-MS) Netherlands several divisions are located in Woerden.
B-MS is originally an American company and has offices worldwide. B-MS has operated for over 40 years In the Netherlands and is a leader in innovative medicines and health products.
For more information about B-MS International, visit: http://www.bms.com/
Squibb settled in 1967 in The Hague. Bristol-Myers since 1971 in the Netherlands. In 1989 both companies merged and Woerden was chosen as a location for BMS.
B-MS has 35,000 employees worldwide, of which 110 work in the Netherlands.
Global B-MS had 2008 sales of $ 20.6 billion.
In 2008, $ 3.6 billion invested in the development of new drugs (17.4% of revenue in 2007 was 17.0%).
B-MS is represented in the associations Nefarma, Netherlands Association of Innovative Drugs and AmCham, American Chamber of Commerce. Both are active in the field of advocacy for the innovative pharmaceutical industry. Topics include: authorization and reimbursement of new drugs, the funding of medicines and promote a favorable climate for innovation in the Netherlands. For more information about the industry, visit: http://www.nefarma.nl or http://www.amchampc.org
The mission of our company is focused on the life of man to the length and quality of life by developing innovative medicines and health products. The research of B-MS is focused on disease areas where there is a medical need, such as cancer, HIV / AIDS, diabetes, rheumatism, hepatitis, schizophrenia, heart disease and obesity.
A very strong phrase that we recently came across describes a “war going on in the generics industry” as a result of the preference policy, which people have claimed has…
Bioceros was founded as a service company built on the immunology expertise of its founders. Additional cell line expertise was added when you joined in 2007. What made this combination…
Clearly the end of 2010 was an exciting time for you. As you entered the transition period as the new CEO of OctoPlus, you also participated in the equity raising.…
As the founder of the Institute of Young Entrepreneurs at the Delft University of Technology and an enthusiastic promoter of innovation and new technologies, what do you believe distinguishes a…
We do not often meet companies that have been successful at retaining their manufacturing facilities in the Netherlands. How and why did former Katwijk Farma -and now Apotex- succeed to…
Pfizer is well placed for the next generation of growth. Coming off great M&A’s and now restructuring internally, (from the country structure to the business units). After closing 2010, the…
Certain cities have specific institutions, foundations, or in this case, science parks that serve as a microcosm for that city. How does Utrecht Science Park embody the identity and strengths…
IMS Health sets itself apart because of its global reach, while mastering local expertise. Clearly, every market is one of a kind. What is so particular about the Dutch market?…
As the chairman of a consortium that has been working towards both medical and technological progress in the region, how have you seen this progress taking place in the Netherlands…
While doing our research we couldn’t help but notice that you are quite passionate about issues related to healthcare and an avid proponent of healthcare reform. In this vein, what…
Deloitte is renowned for its strong network of international expertise. Yet every market has its own particularities… Having spent 16 years with the company, in your opinion, what is it…
Your role as Chair of the Executive Board is a mix between CEO and CMO. On a daily basis, which do you see yourself as more – the Chief Executive…
See our Cookie Privacy Policy Here
